Related Experiment Video
Updated: Dec 27, 2025
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
MEX3A knockdown inhibits the development of pancreatic ductal adenocarcinoma
Xing Wang1, Yu-Qiang Shan2, Qing-Quan Tan1
11Department of Pancreatic Surgery, West China Hospital, Sichuan University, No 37 Guo Xue Alley, Chengdu, 610041 Sichuan China.
Background:
Pancreatic ductal adenocarcinoma (PDA) is one of the most serious causes of death in the world due to its high mortality and inefficacy treatments. MEX3A was first identified in nematodes and was associated with tumor formation and may promote cell proliferation and tumor metastasis. So far, nothing is known about the relationship between MEX3A and PDA.
Methods:
In this study, the expression level of MEX3A in PDA tissues was measured by immunohistochemistry. The qRT-PCR and western blot were used to identify the constructed MEX3A knockdown cell lines, which was further used to construct mouse xenotransplantation models. Cell proliferation, colony formation, cell apoptosis and migration were detected by MTT, colony formation, flow cytometry and Transwell.
Results:
This study showed that MEX3A expression is significantly upregulated in PDA and associated with tumor grade. Loss-of-function studies showed that downregulation of MEX3A could inhibit cell growth in vitro and in vivo. Moreover, it was demonstrated that knockdown of MEX3A in PDA cells promotes apoptosis by regulating apoptosis-related factors, and inhibits migration through influencing EMT. At the same time, the regulation of PDA progression by MEX3A involves changes in downstream signaling pathways including Akt, p-Akt, PIK3CA, CDK6 and MAPK9.
Conclusions:
We proposed that MEX3A is associated with the prognosis and progression of PDA,which can be used as a potential therapeutic target.
Insights
MEX3A is upregulated in pancreatic ductal adenocarcinoma (PDA) and drives tumor growth. Inhibiting MEX3A suppresses PDA progression, suggesting it's a potential therapeutic target for this deadly cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDA) presents a significant global health challenge due to high mortality and limited treatment options.
- MEX3A, a gene linked to tumor formation in nematodes, has an unknown role in PDA.
- Understanding novel molecular players like MEX3A is crucial for advancing PDA treatment strategies.
Purpose of the Study:
- To investigate the role and clinical significance of MEX3A in pancreatic ductal adenocarcinoma.
- To determine if MEX3A expression correlates with PDA progression and patient prognosis.
- To explore MEX3A as a potential therapeutic target for PDA.
Main Methods:
- Immunohistochemistry was used to assess MEX3A expression in PDA tissues.
- Quantitative reverse transcription PCR (qRT-PCR) and Western blot confirmed MEX3A knockdown in cell lines.
- In vitro (MTT, colony formation, flow cytometry, Transwell) and in vivo (mouse xenotransplantation) models evaluated the functional impact of MEX3A downregulation.
Main Results:
- MEX3A expression is significantly elevated in PDA tissues and correlates with tumor grade.
- Downregulating MEX3A inhibited PDA cell proliferation, colony formation, and migration both in vitro and in vivo.
- MEX3A knockdown promoted apoptosis and suppressed epithelial-mesenchymal transition (EMT), impacting key signaling pathways (Akt, PI3K/Akt, MAPK).
Conclusions:
- MEX3A is significantly associated with the progression and poor prognosis of pancreatic ductal adenocarcinoma.
- Targeting MEX3A represents a promising therapeutic strategy for PDA.
- Further research into MEX3A's regulatory mechanisms could uncover new avenues for PDA treatment.
